Use of Catestatin to Mobilize Fat from Adipose Tissue by Regulating Adrenergic and Leptin Signaling
Tech ID: 22551 / UC Case 2012-314-0
BackgroundChromogranin A (CHGA/Chga), a 48-kDa acidic secretory proprotein, gives rise to several peptides of biological importance, which include the dysglycemic hormone pancreastatin, the vasodilator vasostatin, and the antihypertensive peptide catestatin that inhibits catecholamine release. Initially identified as a physiological brake in catecholamine secretion, catestatin has been established as a pleiotropic hormone having effects on promoting angiogenesis and lowering blood pressure.
Technology DescriptionScientists at the University of California, San Diego have discovered that catestatin reduces adipose tissue weight by stimulating breakdown of fat (lipolysis) and disposing of the released fatty acids by oxidation in both liver and adipose tissue. This technology supports an essential role of the endogenous bioactive peptide catestatin in restoring homeostasis during metabolic disorders by controlling catecholamine release and lipid disposal via modulation of adrenergic and leptin signaling. Therefore, CST may be developed as an anti-obesity agent.
- Bandyopadhyay GK, Vu CU, Gentile S, Lee H, Biswas N, Chi NW, O'Connor DT, Mahata SK. Catestatin (Chromogranin A352-372): Novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem. 2012 Apr 25. [Epub ahead of print] - 04/25/2012
catestatin, triglyceride, glycerol, fatty acid
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- A Novel Biomarker for Irritable Bowel Syndrome and Other Stress Disorders
- MicroRNA Therapeutics for Augmenting Blood Vessel Growth
- Device to Characterize Gas Transport Properties Of Cell-Free Oxygen Carriers And Red Blood Cells
- Hepatitis C Virus Genotype 1b Cell Cultures
- Novel Diuretic and Inhibitor of Gastric Acid Secretion